Synthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma

Chemical Biology and Drug Design

Volumn 82, Issue 5, 2013, Pages 520-533

  Barile, Elisa ^a   De, Surya K ^a   Feng, Yongmei ^a   Chen, Vida ^a   Yang, Li ^a   Ronai, Ze'ev ^a   Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

AKT inhibitors; Cancer; Drug discovery; Melanoma; NF B inhibitors

Indexed keywords

3 [3 (1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 PHENYLQUINOLIN 2 (1H) ONE; 3 [3 (1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 6 BROMO 4 PHENYLQUINOLIN 2 (1H) ONE; 3 [3 (1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 6 METHYL 4 PHENYLQUINOLIN 2 (1H) ONE; 3 [3 (5 BROMO 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 6 CHLORO 4 PHENYLQUINOLIN 2 (1H) ONE; 3 [3 (5,6 DIFLUORO 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 (3,4 DIFLUOROPHENYL) 6 FLUOROQUINOLIN 2 (1H) ONE; 3 [3 (5,6 DIFLUORO 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 6 FLUORO 4 (4 FLUOROPHENYL)QUINOLIN 2 (1H) ONE; 6 CHLORO 3 [3 (1 METHYL 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 PHENYLQUINOLIN 2 (1H) ONE; 6 CHLORO 3 [3 (5 FLUORO 1 BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 1 METHYL 4 PHENYLQUINOLIN 2 (1H) ONE; 6 CHLORO 3 [3 (5 FLUORO 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 PHENYLQUINOLIN 2 (1H) ONE; 6 CHLORO 3 [3 (5 METHYL 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 PHENYLQUINOLIN 2 (1H) ONE; 6 CHLORO 3 [3 (5,6 DIFLUORO 1 BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 (4 ETHOXYPHENYL)QUINOLIN 2 (1H) ONE; 6 CHLORO 3 [3 (5,6 DIFLUORO 1 BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 (PARA TOLYL)QUINONOLIN 2 (1H) ONE; 6 CHLORO 3 [3 (5,6 DIFLUORO 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 (4 FLUOROPHENYL) QUINOLIN 2 (1H) ONE; 6 CHLORO 3 [3 (5,6 DIFLUORO 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 (4 METHOXYPHENYL)QUINOLINE 2 (1H) ONE; 6 CHLORO 3 [3 (5,6 DIFLUORO 1H DIFLUOROPHENYL)]QUINOLIN 2 (1H) ONE; 6 CHLORO 4 (4 CHLOROPHENYL) 3 (3 (5,6 DIFLUORO 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL QUINOLIN 2 (1H) ONE; 6 FLUORO 3 [3 (5 FLUORO 1H BENZO[D]IMIDAZOL 2 YL)ACRYLOYL] 4 (4 FLUOROPHENYL)QUINOLIN 2(H) ONE; ANTINEOPLASTIC AGENT; BI 69A11; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

AKT INHIBITORS; CANCER; DRUG DISCOVERY; MELANOMA; NF-ΚB INHIBITORS;

ANIMALS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; HUMANS; MELANOMA; MICE; MICE, NUDE; NF-KAPPA B; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 84885870113     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12177     Document Type: Article

References (31)

1. Cicenas J. (2008) The potential role of Akt phosphorylation in human cancers. Int J Biol Markers;23:1-9.
2. Dhawan P., Singh A.B., Ellis D.L., Richmond A. (2002) Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res;62:7335-7342.
3. Madhunapantula S.V., Robertson G.P. (2009) The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res;22:400-419.
4. Shaw R.J., Cantley L.C. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature;441:424-430.
5. Ueda Y., Richmond A. (2006) NF-kappaB activation in melanoma. Pigment Cell Res;19:112-124.
6. Yang J., Richmond A. (2001) Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res;61:4901-4909.
7. Ghosh S., Karin M. (2002) Missing pieces in the NF-kappaB puzzle. Cell;109(Suppl):S81-S96.
8. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J;17:2215-2223.
9. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. Jr (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol;19:5785-5799.
10. Micheau O., Lens S., Gaide O., Alevizopoulos K., Tschopp J. (2001) NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol;21:5299-5305.
11. Ravi R., Bedi G.C., Engstrom L.W., Zeng Q., Mookerjee B., Gelinas C., Fuchs E.J., Bedi A. (2001) Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol;3:409-416.
12. Coffer P.J., Jin J., Woodgett J.R. (1998) Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J;335(Pt1):1-13.
13. Cully M., You H., Levine A.J., Mak T.W. (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer;6:184-192.
14. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell;91:231-241.
15. Kandel E.S., Skeen J., Majewski N., Di Cristofano A., Pandolfi P.P., Feliciano C.S., Gartel A., Hay N. (2002) Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol;22:7831-7841.
16. Forino M., Jung D., Easton J.B., Houghton P.J., Pellecchia M. (2005) Virtual docking approaches to protein kinase B inhibition. J Med Chem;48:2278-2281.
17. Gaitonde S., De S.K., Tcherpakov M., Dewing A., Yuan H., Riel-Mehan M., Krajewski S., Pellecchia M., Ronai Z. (2009) BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res;22:187-195.
18. Feng Y., Barile E., De S.K., Stebbins J.L., Cortez A., Aza-Blanc P., Villanueva J., Heryl M., Krajewski S., Pellecchia M., Ronai Z.A., Chiang G. (2011) Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-kappaB pathways. Pigment Cell Melanoma Res;24:703-713.
19. Feng Y., Lau E., Scortegagna M., Ruller C., De S.K., Barile E., Krajewski S., Aza-Blanc P., Williams R., Pinkerton A.B., Jackson M., Chin L., Pellecchia M., Bosenberg M., Ronai Z.A. (2012) Inhibition of melanoma development in the Nras((Q61K)):Ink4a(-/-) mouse model by the small molecule BI-69A11. Pigment Cell Melanoma Res;26:136-142.
20. Kelm J.M., Timmins N.E., Brown C.J., Fussenegger M., Nielsen L.K. (2003) Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng;83:173-180.
21. Jia C.S., Dong Y.W., Tu S.J., Wang G.W. (2007) Microwave-assisted solvent-free synthesis of substituted 2-quinolones. Tetrahedron;63:892-897.
22. Kobayashi Y., Harayama T. (2009) A concise and versatile synthesis of viridicatin alkaloids from cyanoacetanilides. Org Lett;11:1603-1606.
23. Prezent M.A., Dorokhov V.A. (2003) Camps reaction for the synthesis of 3-RS-4-arylquinolin-2-ones. Russ Chem B+;52:2454-2456.
24. Ribeiro N., Tabaka H., Peluso J., Fetzer L., Nebigil C., Dumont S., Muller C.D., Désaubry L. (2007) Synthesis of 3-O-methylviridicatin analogues with improved anti-TNF-alpha properties. Bioorg Med Chem Lett;17:5523-5524.
25. Filler R., Saha R. (2009) Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights. Future Med Chem;1:777-791.
26. Park B.K., Kitteringham N.R., O'Neill P.M. (2001) Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol;41:443-470.
27. Purser S., Moore P.R., Swallow S., Gouverneur V. (2008) Fluorine in medicinal chemistry. Chem Soc Rev;37:320-330.
28. Plantevin Krenitsky V., Nadolny L., Delgado M., Ayala L., Clareen S.S., Hilgraf R., Albers R. et al. (2012) Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett;22:1433-1438.
29. Krenitsky V.P., Delgado M., Nadolny L., Sahasrabudhe K., Ayala L., Clareen S.S., Hilgraf R. et al. (2012) Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. Bioorg Med Chem Lett;22:1427-1432.
30. Muller K., Faeh C., Diederich F. (2007) Fluorine in pharmaceuticals: looking beyond intuition. Science;317:1881-1886.
31. Griffith L.G., Swartz M.A. (2006) Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol;7:211-224.